https://scholars.lib.ntu.edu.tw/handle/123456789/594785
標題: | Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk | 作者: | Hsu Y.-C. Nguyen M.H. Mo L.-R. MING-SHIANG WU Yang T.-H. CHIEH-CHANG CHEN Tseng C.-H. Tai C.-M. Wu C.-Y. Lin J.-T. Tanaka Y. Chang C.-Y. |
公開日期: | 2019 | 出版社: | Blackwell Publishing Ltd | 卷: | 49 | 期: | 1 | 起(迄)頁: | 107-115 | 來源出版物: | Alimentary Pharmacology and Therapeutics | 摘要: | Background: There remains an unmet need for convenient biomarkers to assess the risks of discontinuing nucleos(t)ide analogues (NAs) in chronic hepatitis B (CHB). Aim: To investigate if hepatitis B core-related antigen (HBcrAg) is an independent of surface antigen (HBsAg) for risk prediction of NA cessation. Methods: This prospective multicentre study enrolled 135 CHB patients who stopped entecavir or tenofovir after achieving viral remission for a median of 25.2?months. All patients stopped NA with negative HBeAg and undetectable viral DNA, and were then observed for clinical relapse and HBsAg loss. Predictors including HBsAg and HBcrAg levels were explored using Cox proportional hazard model and weighted to develop a risk score. Results: During a median follow-up of 25.9?months, clinical relapse and HBsAg loss occurred in 66 and eight patients, respectively, with a 5-year cumulative incidence of 56.1% (95% CI 46.7-66.0%) and 8.8% (95% CI 4.3-17.4%), respectively. HBcrAg was an independent relapse predictor, as well as HBsAg, age, ALT and tenofovir use. A score (SCALE-B) was calculated by the equation of 35*HBsAg (log?IU/mL)?+?20*HBcrAg (log U/mL)?+?2*age (year)?+?ALT (U/L)?+?40 for tenofovir use. The concordance rates for clinical relapse were 0.87, 0.88, 0.87, 0.85 and 0.90 at 1, 2, 3, 4 and 5?years, respectively. Moreover, HBsAg loss occurred exclusively in low-risk patients predicted by the score. Conclusions: Serum HBcrAg and HBsAg levels were independent predictors of off-NA relapse and can be factored into a risk score to guide treatment cessation in patients with CHB. ? 2018 John Wiley & Sons Ltd |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85056697891&doi=10.1111%2fapt.15058&partnerID=40&md5=3db5b9bb408268f20422b79039d14dee https://scholars.lib.ntu.edu.tw/handle/123456789/594785 |
ISSN: | 0269-2813 | DOI: | 10.1111/apt.15058 | SDG/關鍵字: | alanine aminotransferase; entecavir; hepatitis B surface antigen; nucleoside analog; tenofovir; virus DNA; antivirus agent; biological marker; entecavir; guanine; hepatitis B core antigen; hepatitis B surface antigen; adult; Article; chronic hepatitis B; drug use; female; follow up; human; low risk patient; major clinical study; male; prediction; priority journal; prospective study; relapse; remission; risk factor; blood; chronic hepatitis B; clinical trial; incidence; metabolism; middle aged; multicenter study; recurrent disease; treatment withdrawal; Adult; Antiviral Agents; Biomarkers; DNA, Viral; Female; Guanine; Hepatitis B Core Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; Humans; Incidence; Male; Middle Aged; Prospective Studies; Recurrence; Tenofovir; Withholding Treatment |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。